Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Fms-like tyrosine kinase 3 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Fms-like tyrosine kinase 3 inhibitors: Overview
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase (RTK), a membrane-bound receptor with an intrinsic tyrosine kinase activity that is highly expressed in hematopoietic stem/progenitor cells and regulates hematopoietic differentiation and proliferation. Activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). FLT3 is made up of 5 functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), a tyrosine kinase domain (TKD), and a small C-terminal domain. FLT3 is a promising molecular target in a subset of AML cases, and the therapeutic effects of FLT3 inhibitors have been reported in AML patients with FLT3 mutations. The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new AML therapy. A number of resistance mechanisms to FLT3 inhibitors have been identified in preclinical and clinical studies, including acquired FLT3 resistance mutations, other gene mutations such as NRAS, and altered protein expression such as that of FL, AXL kinase, Pim kinase, or FGF2.
Report Highlights
This segment of the Fms-like tyrosine kinase 3 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fms-like tyrosine kinase 3 inhibitors Emerging Drugs
Further product details are provided in the report……..
Fms-like tyrosine kinase 3 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Fms-like tyrosine kinase 3 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Fms-like tyrosine kinase 3 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Fms-like tyrosine kinase 3 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fms-like tyrosine kinase 3 inhibitors drugs.
Fms-like tyrosine kinase 3 inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Fms-like tyrosine kinase 3 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Fms-like tyrosine kinase 3 inhibitors: Overview
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase (RTK), a membrane-bound receptor with an intrinsic tyrosine kinase activity that is highly expressed in hematopoietic stem/progenitor cells and regulates hematopoietic differentiation and proliferation. Activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML). FLT3 is made up of 5 functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), a tyrosine kinase domain (TKD), and a small C-terminal domain. FLT3 is a promising molecular target in a subset of AML cases, and the therapeutic effects of FLT3 inhibitors have been reported in AML patients with FLT3 mutations. The exploration of small-molecule inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new AML therapy. A number of resistance mechanisms to FLT3 inhibitors have been identified in preclinical and clinical studies, including acquired FLT3 resistance mutations, other gene mutations such as NRAS, and altered protein expression such as that of FL, AXL kinase, Pim kinase, or FGF2.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Fms-like tyrosine kinase 3 inhibitors R&D. The therapies under development are focused on novel approaches for Fms-like tyrosine kinase 3 inhibitors.
This segment of the Fms-like tyrosine kinase 3 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fms-like tyrosine kinase 3 inhibitors Emerging Drugs
- CG-806: Aptose Biosciences
- Quizartinib: Daiichi Sankyo Company
Further product details are provided in the report……..
Fms-like tyrosine kinase 3 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Fms-like tyrosine kinase 3 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Fms-like tyrosine kinase 3 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Fms-like tyrosine kinase 3 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Fms-like tyrosine kinase 3 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fms-like tyrosine kinase 3 inhibitors drugs.
Fms-like tyrosine kinase 3 inhibitors Report Insights
- Fms-like tyrosine kinase 3 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Fms-like tyrosine kinase 3 inhibitors drugs?
- How many Fms-like tyrosine kinase 3 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Fms-like tyrosine kinase 3 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fms-like tyrosine kinase 3 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fms-like tyrosine kinase 3 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Aptose Biosciences
- Daiichi Sankyo Company
- Celon Pharma
- AROG Pharmaceuticals
- Pfizer
- Ascentage Pharma
- Pharos I&BT Co
- Novartis Oncology
- Exelixis
- Ipsen
- CG-806
- Quizartinib
- Research program: small molecule anti-cancer therapeutics
- Crenolanib
- Olverembatinib
- PHI-101
- Midostaurin
- Cabozantinib
Introduction
Executive Summary
Fms-like tyrosine kinase 3 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Fms-like tyrosine kinase 3 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Fms-like tyrosine kinase 3 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Fms-like tyrosine kinase 3 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Quizartinib: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Coltuximab Ravtansine: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
CG-806: Aptose Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
RC58: RemeGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Fms-like tyrosine kinase 3 inhibitors Key Companies
Fms-like tyrosine kinase 3 inhibitors Key Products
Fms-like tyrosine kinase 3 inhibitors- Unmet Needs
Fms-like tyrosine kinase 3 inhibitors- Market Drivers and Barriers
Fms-like tyrosine kinase 3 inhibitors- Future Perspectives and Conclusion
Fms-like tyrosine kinase 3 inhibitors Analyst Views
Fms-like tyrosine kinase 3 inhibitors Key Companies
Appendix
Executive Summary
Fms-like tyrosine kinase 3 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Fms-like tyrosine kinase 3 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Fms-like tyrosine kinase 3 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Fms-like tyrosine kinase 3 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Quizartinib: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Coltuximab Ravtansine: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
CG-806: Aptose Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
RC58: RemeGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Fms-like tyrosine kinase 3 inhibitors Key Companies
Fms-like tyrosine kinase 3 inhibitors Key Products
Fms-like tyrosine kinase 3 inhibitors- Unmet Needs
Fms-like tyrosine kinase 3 inhibitors- Market Drivers and Barriers
Fms-like tyrosine kinase 3 inhibitors- Future Perspectives and Conclusion
Fms-like tyrosine kinase 3 inhibitors Analyst Views
Fms-like tyrosine kinase 3 inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Fms-like tyrosine kinase 3 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Fms-like tyrosine kinase 3 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Fms-like tyrosine kinase 3 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Fms-like tyrosine kinase 3 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
